Association of Celecoxib Use With Decreased Opioid Requirements After Head and Neck Cancer Surgery With Free Tissue Reconstruction | Head and Neck Cancer | JAMA Otolaryngology–Head & Neck Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
Parker  SL, Tong  T, Bolden  S, Wingo  PA.  Cancer statistics, 1997.  CA Cancer J Clin. 1997;47(1):5-27.PubMedGoogle ScholarCrossref
2.
Keefe  FJ, Manuel  G, Brantley  A, Crisson  J.  Pain in the head and neck cancer patient: changes over treatment.  Head Neck Surg. 1986;8(3):169-176.PubMedGoogle ScholarCrossref
3.
Silverberg  E.  Cancer statistics. 1986.  CA Cancer J Clin. 1986;36(1):9-25.PubMedGoogle ScholarCrossref
4.
Foley  KM, Inturrisi  CE.  Analgesic drug therapy in cancer pain: principles and practice.  Med Clin North Am. 1987;71(2):207-232.PubMedGoogle ScholarCrossref
5.
Raj  P, Phero  J.  Pain Control in Cancer of the Head and Neck. Philadelphia, PA: Saunders; 1987.
6.
Chua  KS, Reddy  SK, Lee  MC, Patt  RB.  Pain and loss of function in head and neck cancer survivors.  J Pain Symptom Manage. 1999;18(3):193-202.PubMedGoogle ScholarCrossref
7.
Murphy  BA, Dietrich  MS, Wells  N,  et al.  Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation.  Head Neck. 2010;32(1):26-37.PubMedGoogle Scholar
8.
Kehlet  H, Holte  K.  Effect of postoperative analgesia on surgical outcome.  Br J Anaesth. 2001;87(1):62-72.PubMedGoogle ScholarCrossref
9.
Macdonald  DJ.  Anaesthesia for microvascular surgery. A physiological approach.  Br J Anaesth. 1985;57(9):904-912.PubMedGoogle ScholarCrossref
10.
Dort  JC, Farwell  DG, Findlay  M,  et al.  Optimal perioperative care in major head and neck cancer surgery with free flap reconstruction: a consensus review and recommendations from the enhanced recovery after surgery society.  JAMA Otolaryngol Head Neck Surg. 2017;143(3):292-303.PubMedGoogle ScholarCrossref
11.
Jungquist  C, Smith  K, Wiltse Nicely  K, Polomano  R.  Monitoring hospitalized adult patients for opioid-induced sedation and respiratory depression.  AM J Nurs. 2017;117(Supple, 1).Google Scholar
12.
Rudd  R, Seth  P, Scholl  L, David  F.  Increases in drug and opioid-involved overdose deaths—United States 2010-2015.  MMWR Morb Mortal Wkly. 2016;65(5051):1445-1452.Google ScholarCrossref
13.
IMS Health National Prescription Audit (NPATM). Preliminary update on Opioid Pain Reliever Prescription rates nationally and by state 2010-2013. 2014. https://www.cdc.gov/drugoverdose/opioids/prescribed.html. Accessed February 18, 2018.
14.
Beaver  WT.  Combination analgesics.  Am J Med. 1984;77(3A):38-53.PubMedGoogle ScholarCrossref
15.
Straube  S, Derry  S, McQuay  HJ, Moore  RA.  Effect of preoperative Cox-II-selective NSAIDs (coxibs) on postoperative outcomes: a systematic review of randomized studies.  Acta Anaesthesiol Scand. 2005;49(5):601-613.PubMedGoogle ScholarCrossref
16.
Kroin  JS, Buvanendran  A, McCarthy  RJ, Hemmati  H, Tuman  KJ.  Cyclooxygenase-2 inhibition potentiates morphine antinociception at the spinal level in a postoperative pain model.  Reg Anesth Pain Med. 2002;27(5):451-455.PubMedGoogle ScholarCrossref
17.
Sekiguchi  H, Inoue  G, Nakazawa  T,  et al.  Loxoprofen sodium and celecoxib for postoperative pain in patients after spinal surgery: a randomized comparative study.  J Orthop Sci. 2015;20(4):617-623.PubMedGoogle ScholarCrossref
18.
Huang  YM, Wang  CM, Wang  CT, Lin  WP, Horng  LC, Jiang  CC.  Perioperative celecoxib administration for pain management after total knee arthroplasty - a randomized, controlled study.  BMC Musculoskelet Disord. 2008;9:77.PubMedGoogle ScholarCrossref
19.
Mardani-Kivi  M, Karimi Mobarakeh  M, Haghighi  M,  et al.  Celecoxib as a pre-emptive analgesia after arthroscopic knee surgery; a triple-blinded randomized controlled trial.  Arch Orthop Trauma Surg. 2013;133(11):1561-1566.PubMedGoogle ScholarCrossref
20.
Kahlenberg  CA, Patel  RM, Knesek  M, Tjong  VK, Sonn  K, Terry  MA.  Efficacy of celecoxib for early postoperative pain management in hip arthroscopy: a prospective randomized placebo-controlled study.  Arthroscopy. 2017;33(6):1180-1185.PubMedGoogle ScholarCrossref
21.
Parsa  AA, Sprouse-Blum  AS, Jackowe  DJ, Lee  M, Oyama  J, Parsa  FD.  Combined preoperative use of celecoxib and gabapentin in the management of postoperative pain.  Aesthetic Plast Surg. 2009;33(1):98-103.PubMedGoogle ScholarCrossref
22.
Sun  T, Sacan  O, White  PF, Coleman  J, Rohrich  RJ, Kenkel  JM.  Perioperative versus postoperative celecoxib on patient outcomes after major plastic surgery procedures.  Anesth Analg. 2008;106(3):950-958.PubMedGoogle ScholarCrossref
23.
Parsa  AA, Soon  CW, Parsa  FD.  The use of celecoxib for reduction of pain after subpectoral breast augmentation.  Aesthetic Plast Surg. 2005;29(6):441-444.PubMedGoogle ScholarCrossref
24.
Aynehchi  BB, Cerrati  EW, Rosenberg  DB.  The efficacy of oral celecoxib for acute postoperative pain in face-lift surgery.  JAMA Facial Plast Surg. 2014;16(5):306-309.PubMedGoogle ScholarCrossref
25.
Wax  MK, Reh  DD, Levack  MM.  Effect of celecoxib on fasciocutaneous flap survival and revascularization.  Arch Facial Plast Surg. 2007;9(2):120-124.PubMedGoogle ScholarCrossref
26.
Derry  S, Moore  RA.  Single dose oral celecoxib for acute postoperative pain in adults.  Cochrane Database Syst Rev. 2013;10(10):CD004233.PubMedGoogle Scholar
27.
Curfman  GD, Morrissey  S, Drazen  JM. Expression of concern: Bombardier et al.  “Comparison of upper gastrointestinal toxicity of refecoxib and naproxen in patients with rheumatoid arthritis,” N Engl J Med. 2000;343:1520-8.  N Engl J Med. 2005;353(26):2813-2814.PubMedGoogle ScholarCrossref
28.
Silverstein  FE, Faich  G, Goldstein  JL,  et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.  JAMA. 2000;284(10):1247-1255.PubMedGoogle ScholarCrossref
29.
Gasparini  G, Longo  R, Sarmiento  R, Morabito  A.  Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?  Lancet Oncol. 2003;4(10):605-615.PubMedGoogle ScholarCrossref
30.
Lau  L, Hansford  LM, Cheng  LS,  et al.  Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma.  Oncogene. 2007;26(13):1920-1931.PubMedGoogle ScholarCrossref
31.
Veettil  SK, Lim  KG, Ching  SM, Saokaew  S, Phisalprapa  P, Chaiyakunapruk  N.  Effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs on the incidence of recurrent colorectal adenomas: a systematic review with meta-analysis and trial sequential analysis of randomized clinical trials.  BMC Cancer. 2017;17(1):763.PubMedGoogle ScholarCrossref
32.
Talmi  YP, Horowitz  Z, Pfeffer  MR,  et al.  Pain in the neck after neck dissection.  Otolaryngol Head Neck Surg. 2000;123(3):302-306.PubMedGoogle ScholarCrossref
33.
Gil  Z, Smith  DB, Marouani  N, Khafif  A, Fliss  DM.  Treatment of pain after head and neck surgeries: control of acute pain after head and neck oncological surgeries.  Otolaryngol Head Neck Surg. 2006;135(2):182-188.PubMedGoogle ScholarCrossref
34.
Sommer  M, Geurts  JW, Stessel  B,  et al.  Prevalence and predictors of postoperative pain after ear, nose, and throat surgery.  Arch Otolaryngol Head Neck Surg. 2009;135(2):124-130.PubMedGoogle ScholarCrossref
35.
Inhestern  J, Schuerer  J, Illge  C,  et al.  Pain on the first postoperative day after head and neck cancer surgery.  Eur Arch Otorhinolaryngol. 2015;272(11):3401-3409.PubMedGoogle ScholarCrossref
36.
Mantha  S, Thisted  R, Foss  J, Ellis  JE, Roizen  MF.  A proposal to use confidence intervals for visual analog scale data for pain measurement to determine clinical significance.  Anesth Analg. 1993;77(5):1041-1047.PubMedGoogle ScholarCrossref
37.
Abdelhalim  AA, Al Harethy  S, Moustafa  M.  Lornoxicam versus tramadol for post-operative pain relief in patients undergoing ENT procedures.  Saudi J Anaesth. 2014;8(1):38-44.PubMedGoogle ScholarCrossref
38.
Issioui  T, Klein  KW, White  PF,  et al.  Cost-efficacy of rofecoxib versus acetaminophen for preventing pain after ambulatory surgery.  Anesthesiology. 2002;97(4):931-937.PubMedGoogle ScholarCrossref
39.
Issioui  T, Klein  KW, White  PF,  et al.  The efficacy of premedication with celecoxib and acetaminophen in preventing pain after otolaryngologic surgery.  Anesth Analg. 2002;94(5):1188-1193.PubMedGoogle ScholarCrossref
40.
Dalen  JE.  Selective COX-2 Inhibitors, NSAIDs, aspirin, and myocardial infarction.  Arch Intern Med. 2002;162(10):1091-1092.PubMedGoogle ScholarCrossref
41.
Tohgi  H, Konno  S, Tamura  K, Kimura  B, Kawano  K.  Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin.  Stroke. 1992;23(10):1400-1403.PubMedGoogle ScholarCrossref
Original Investigation
From the American Head and Neck Society
November 2018

Association of Celecoxib Use With Decreased Opioid Requirements After Head and Neck Cancer Surgery With Free Tissue Reconstruction

Author Affiliations
  • 1Otolaryngology–Head and Neck Surgery, The University of Utah School of Medicine, Salt Lake City
JAMA Otolaryngol Head Neck Surg. 2018;144(11):988-994. doi:10.1001/jamaoto.2018.0284
Key Points

Question  Does the addition of celecoxib to the standard analgesia regimen decrease the amount of opioid use in patients after head and neck cancer (HNC) surgery and reconstruction with free tissue?

Findings  In this matched-cohort study, 51 patients who received celecoxib after HNC surgery with free tissue reconstruction had significantly decreased perioperative opioid requirements compared with 51 matched patients who did not receive celecoxib. There were no differences in complication rates between the 2 groups.

Meaning  Celecoxib was associated with a decrease in opioid requirements after HNC surgery with free tissue reconstruction and should remain a consideration for perioperative analgesia in select patients.

Abstract

Importance  Head and neck cancer (HNC) surgery with free tissue reconstruction is associated with considerable postoperative pain. Opioids are typically used but can have adverse effects, including respiratory depression and high rates of dependence and addiction. Safe alternative analgesics that minimize opioid requirements are beneficial in HNC surgery.

Objective  To investigate the association of celecoxib use with opioid requirements in the postoperative setting after HNC surgery with free tissue reconstruction.

Design, Setting, and Participants  A retrospective, matched-cohort study of 147 patients who had undergone HNC surgery with free tissue reconstruction between June 2015 and Sept 2017 in an academic cancer hospital. Patients were separated into groups based on whether celecoxib had been used perioperatively or not. These groups were then matched by stage and site resulting in 102 included participants (51 celecoxib, 51 control).

Main Outcomes and Measures  Oral, intravenous (IV), and total morphine equivalents used in the postoperative setting per patient per day.

Results  There were 51 patients in the celecoxib cohort (19 women and 32 men) and 51 patients in the control cohort (20 women and 31 men) who met inclusion criteria after clinicopathologic data were matched. The mean age of the celecoxib and control cohorts was 61.6 years and 66.1 years, respectively. Treatment with celecoxib in the postoperative setting was associated with decreased mean use of opioids in oral (mean difference, 9.9 mg/d; 95% CI, −1.2 to 21.1), IV (mean difference, 3.9 mg/d; 95% CI, 1.0-6.8), and total (mean difference, 14 mg/d; 95% CI, 2.6-25.4) amount of morphine equivalents per day. When patients were matched to surgical procedure, the effect was more significant. Patients who underwent composite oral resection and received celecoxib had decreased opioid use in oral (mean difference, 25 mg/d; 95% CI, 12.5-25.4), IV (mean difference, 3.4 mg/d; 95% CI, 1.5-5.5), and total (mean difference, 28.4 mg/d; 95% CI, 15.7-41.5) amounts compared with those in the control group. There was no significant difference in complication rates between the 2 cohorts.

Conclusions and Relevance  Use of celecoxib after head and neck cancer surgery and reconstruction with free tissue transfer was associated with a decrease in oral, IV, and total opioid requirements without increasing surgical or flap-related complications.

×